Navigation Links
Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners

BOSTON, Aug. 2, 2012 /PRNewswire/ -- Enlight Biosciences LLC today announced that its newest portfolio company, Knode, has formed strategic partnerships with AstraZeneca and other industry and academic partners. As an Enlight partner, AstraZeneca will collaborate in the development of KNODE's innovative web-based solution for providing a comprehensive view of life science experts and their work.

"Faced with a vast body of scientific information, we expect KNODE will provide an efficient platform to access and mine a broad range of data to identify expert sources across topics and relationships that provide our R&D scientists unique insight into emerging science and opportunities," said John Reynders, Vice President, R&D Information at AstraZeneca. 

According to David Steinberg, KNODE's CEO, "KNODE is preparing to launch a dynamic and automated search platform to help individual researchers, academic institutions and companies to discover new connections to foster community and the exchange of scientific knowledge within and beyond their organizations. It's a next generation networking platform, connecting you with the right experts at the right time."

"The creation of KNODE emerged from Enlight's unique understanding of the challenges faced by the pharmaceutical industry," said Enlight's Chief Business Officer, Baruch Harris, Ph.D. "We are excited to be working with AstraZeneca and our other pharma partners to further develop and apply KNODE'S unique approach to defining scientific expertise and provide our partners with a clear view of the R&D landscape."

Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to proactively address critical unmet industry needs. Enlight has publicly announced the formation of two other companies in addition to KNODE – Entrega and Endra. Entrega is developing a proprietary delivery technology to enable the oral administration of proteins, peptides and difficult-to-deliver small molecules. Endra has commercialized a breakthrough preclinical imaging technology that combines the properties of light-based (optical) imaging with ultrasound to enable advanced live-animal imaging for preclinical research.  


KNODE's web-based life science solution provides a comprehensive view of experts and their content. KNODE is working with some of the world's leading pharmaceutical companies, academic institutions, and researchers to foster the critical network connections that make teams successful. Combining advanced semantic and topic extraction algorithms and a deep biomedical domain expertise, KNODE's solutions address some of the toughest problems of scientific communication and knowledge sharing.

About Enlight

Enlight is a unique entrepreneurial partnership with major pharmaceutical companies and leading academics, focused on pioneering breakthrough innovations for drug discovery and development. Our partners are able to foster the development of high impact enabling technologies and platforms and focus their investment into the innovations that will directly address their most pressing common needs. Enlight was co-founded by PureTech Ventures and academic luminaries led by Dr. H. Robert Horvitz, Enlight's SAB Chair, Nobel Laureate, Howard Hughes Investigator, and Koch Professor of Biology at MIT; Dr. Sam Gambhir, Chair of the Department of Radiology and Chief of the Division of Nuclear Medicine, Stanford; Dr. Rakesh Jain, Cook Professor of Tumor Biology at MGH and Harvard Medical School; and Dr. Raju Kucherlapati, Cabot Professor of Genetics at Harvard Medical School and co-founder of Millennium and Abgenix. Enlight's team also includes an experienced senior pharmaceutical executive, Dr. Bennett Shapiro, PureTech Ventures Senior Partner, former Executive Vice President of Basic Research and Worldwide Licensing at Merck & Co., Inc.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

SOURCE Enlight Biosciences LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. The Partnership at Announces New Partners in National Medicine Abuse Action Campaign
5. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
6. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
7. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
8. Sysmex and Siemens Renew Global Partnership for Hemostasis Solutions and Services
9. GP Strategies Partners with ATR, Inc. to Provide Advanced Procedure Improvement Technology Solutions to the Process Industry
10. inVentiv Medical Management Forms Partnership with Vital Decisions
11. Arbor Pharmaceuticals partners with the Association of Black Cardiologists to further the campaign of "Saving Hearts of a Diverse America"
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
Breaking Medicine News(10 mins):